Business Wire

Global Student Teams Compete in 2nd Annual Susilo Institute Business+Ethics Case Competition in Sweden

16.7.2025 15:00:00 CEST | Business Wire | Press Release

Share

Six finalist teams from around the world gathered in Sweden for the 2nd annual Susilo Institute Business+Ethics Case Competition, hosted by Boston University’s Questrom School of Business.

Organized by the Susilo Institute for Ethics in the Global Economy, the year-long competition challenges students to address complex ethical challenges through rigorous case analysis, team collaboration, and cultural immersion. It began last fall with more than 44 teams representing over 20 universities across 12 countries, and culminated in an immersive, in-person, final round in Stockholm and Östersund, Sweden, from June 1–4, 2025.

Three original case studies written by Questrom MBA students Soleha Patel (’25), Alexander Orta (’25), and Ankit Saraf (’25) under the direction of Professor Greg Stoller anchored the competition. The six teams presented their original analysis and solutions to the Swedish company’s executive teams, who also served as judges. Additionally, teams composed of students from different universities presented their impressions of Swedish culture and proposed a strategic plan for a Swedish candy distributor. The six finalist teams represented Caucasus University (Georgia), Gadjah Mada University (Indonesia), UMass Boston (USA), Stanford University (USA), Tor Vergata University (Italy), and Trinity College Dublin (Ireland). The first-place team from Caucasus University—Giorgi Zanguri, Aleksandre Maisuradze, Mariam Lochoshvili, and Mariam Lortkipanidze—was recognized for their strategic insight, ethical reasoning, and cross-cultural awareness. Stanford University and Trinity College Dublin also placed.

David Epstein, Executive Director of the Susilo Institute, and Claudia Sunberg, Swedish Program Coordinator supported Prof. Stoller’s innovative approach for this competition.

The Susilo Institute for Ethics in the Global Economy is a business-focused ethics center promoting global ethical practices and giving students real exposure to cultural and operational diversity. The competition is a flagship initiative of the Institute, founded through the generosity of Harry Susilo, Chairman and Founder of Sekar Group, an international corporation, and long-time supporter of Boston University. Representing the Susilo family at the finals were Finna Huang and Mark Clay, a director at Sekar Bumi. The competition shows how business education can go beyond the classroom—uniting students from around the world through immersive travel, student-led research, and a rigorous focus on business ethics.

“Some of these presentations have been absolutely fantastic," said Clay. “But what’s really interesting for me this year…was the feedback from the actual owners of the sponsored companies who are saying they are actually gaining valuable insights into ideas that can benefit their companies going forward.”

Soleha Patel (Questrom ’25), one of the case writers, reflected on the experience: “Someone pinch my 13-year-old shy self and tell her that almost a decade later, she’ll be pursuing an MBA, traveling to Sweden, and sitting across from founders and CEOs. I’m beyond grateful to have worked with an amazing team to craft cases for the Susilo Institute’s competition…”

Last year, the finals were held in Indonesia, and featured teams from Mexico, Japan, Germany, Lebanon, Indonesia, and the United States.

About the Boston University Questrom School of Business

Founded in 1913, the Boston University Questrom School of Business is a global top-tier academic research business school. Led by Allen Questrom Professor and Dean, Susan Fournier, Questrom develops business leaders who create value for the world. Questrom redefines transformational business programs, strengthens partnerships with the business community, advances the impact of research on business, and manages the school as a high-performing enterprise committed to excellence with a service mindset. Comprising a renowned full-time faculty of 165 researchers, teaching faculty, and accomplished practitioners, Questrom generates insights to address today’s business challenges and prepares students with the tools they need to succeed from Day 1 in their professional lives. Questrom’s portfolio of academic programs is robust and includes a Top 20 undergraduate program of over 2,200 students; distinctive MBA offerings including 900 students in a full- and part-time MBA, the affordable Online MBA and specialty MBAs in social impact, health, and digital technology; several thriving specialized masters programs in areas including business analytics, mathematical finance, and management studies; and a rigorous PhD program. More than 50,000 Questrom alumni form a powerful global network of leaders driving value creation that changes the world.

QUESTROM MEANS BUSINESS. For more information, visit bu.edu/questrom.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250716118887/en/

Contacts

Press contacts:
Paul Alexander
Tel.: 617-470-9772
Email: pasystem@bu.edu

Jill Totenberg
Tel.: 917-697-6900
Email: jtotenberg@totenberggroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye